SOLASCURE Ltd (SolasCure), a biotechnology company developing a novel treatment to transform chronic wound healing, today ...

The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

Phase II clinical trial to determine the efficacy of Aurase Wound Gel at a higher concentration of the active enzyme Tarumase in venous leg ulcers SOLASCURE Ltd (SolasCure), a biotechnology ...

Subscribe for FREE Using the common hydrogel Gel-MA, they added the amino acid polylysine and platelet-rich blood plasma to create properties that are well-suited to wound care ... Reference: Yan P, ...

Recognises the potential of Aurase Wound Gel to improve outcomes for individuals with calciphylaxis ulcers, a rare and life-threatening condition Represents a new indication for Aurase Wound Gel ...

Using the common hydrogel Gel-MA, they added the amino acid polylysine and platelet-rich blood plasma to create properties that are well-suited to wound care. The result is a hydrogel that is ...